Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
25
VKTX Quote, Financials, Valuation and Earnings
Last price:
$32.29
Seasonality move
:
31.11%
Day range:
$31.85 - $35.21
52-week range:
$18.92 - $43.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.10x
Volume:
8.3M
Avg. volume:
2.6M
1-year change:
-25.06%
Market cap:
$3.6B
Revenue:
--
EPS (TTM):
-$2.12
Analysts' Opinion
-
Consensus RatingViking Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $93.39, Viking Therapeutics, Inc. has an estimated upside of 190.57% from its current price of $32.14.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing 100% downside risk from its current price of $32.14.
Fair Value
-
According to the consensus of 13 analysts, Viking Therapeutics, Inc. has 190.57% upside to fair value with a price target of $93.39 per share.
VKTX vs. S&P 500
-
Over the past 5 trading days, Viking Therapeutics, Inc. has underperformed the S&P 500 by -14.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Viking Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Viking Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Viking Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Viking Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Viking Therapeutics, Inc. reported earnings per share of -$0.81.
Enterprise value:
2.9B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.12x
EV / Free cash flow:
-13.00x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$447K
Return On Assets:
-27.73%
Net Income Margin (TTM):
--
Return On Equity:
-28.62%
Return On Invested Capital:
-28.59%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$290K | -$310K | -$447K | -$87K | -$114K | |
| Operating Income | -$91.8M | -$134M | -$274.8M | -$36.6M | -$98.6M | |
| EBITDA | -$91.5M | -$133.7M | -$274.4M | -$36.5M | -$98.4M | |
| Diluted EPS | -$0.92 | -$0.94 | -$2.12 | -$0.22 | -$0.81 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $224.3M | $165.1M | $381.3M | $936.6M | $738.7M | |
| Total Assets | $224.5M | $166.7M | $382.7M | $937.9M | $739.4M | |
| Current Liabilities | $11.4M | $14.1M | $13.4M | $25.7M | $26.1M | |
| Total Liabilities | $11.4M | $15.4M | $14.4M | $26.4M | $26.4M | |
| Total Equity | $213.1M | $151.3M | $368.2M | $911.4M | $713M | |
| Total Debt | -- | $1.3M | $1M | $755K | $318K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$66.7M | -$74.2M | -$224.6M | -$22M | -$94M | |
| Cash From Investing | -$207.6M | -$524.2M | $272.4M | $25.9M | $160M | |
| Cash From Financing | $281.9M | $611.7M | $2.3M | $2.5M | $480K | |
| Free Cash Flow | -$66.7M | -$74.2M | -$224.6M | -$22M | -$94M | |
VKTX
Sector
Market Cap
$3.6B
$28.1M
Price % of 52-Week High
73.8%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
-0.08%
-1.55%
1-Year Price Total Return
-25.06%
-19.36%
Beta (5-Year)
0.710
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$35.68
200-day SMA
Buy
Level
$30.47
Bollinger Bands (100)
Sell
Level
27.57 - 37.87
Chaikin Money Flow
Sell
Level
-17M
20-day SMA
Sell
Level
$36.09
Relative Strength Index (RSI14)
Sell
Level
35.12
ADX Line
Sell
Level
10.02
Williams %R
Buy
Level
-95.1505
50-day SMA
Sell
Level
$36.34
MACD (12, 26)
Sell
Level
-0.40
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
386.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (95.9227)
Buy
CA Score
(Annual)
Level (0.591)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.9376)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, VKTX has received 12 Buy ratings 1 Hold ratings, and 0 Sell ratings. The VKTX average analyst price target in the past 3 months is $93.39.
-
Where Will Viking Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Viking Therapeutics, Inc. share price will rise to $93.39 per share over the next 12 months.
-
What Do Analysts Say About Viking Therapeutics, Inc.?
Analysts are divided on their view about Viking Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Viking Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is Viking Therapeutics, Inc.'s Price Target?
The price target for Viking Therapeutics, Inc. over the next 1-year time period is forecast to be $93.39 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is VKTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Viking Therapeutics, Inc. is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VKTX?
You can purchase shares of Viking Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Viking Therapeutics, Inc. shares.
-
What Is The Viking Therapeutics, Inc. Share Price Today?
Viking Therapeutics, Inc. was last trading at $32.29 per share. This represents the most recent stock quote for Viking Therapeutics, Inc.. Yesterday, Viking Therapeutics, Inc. closed at $32.14 per share.
-
How To Buy Viking Therapeutics, Inc. Stock Online?
In order to purchase Viking Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get VKTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VKTX
Sector
P/E ratio
--
24.09x
PEG ratio
-0.12x
-0.01x
P/B ratio
5.10x
1.83x
Price / LTM sales
--
1.59x
Growth Metrics
VKTX
Sector
Revenue growth
--
4.68%
Earnings growth
-259.4%
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.90
-$0.18
Profitability
VKTX
Sector
Profitability FY 2024
-$346K
$3.6M
Return on invested capital
-28.59%
-31.87%
Return on assets
-27.73%
-28.18%
Return on equity
-28.62%
-37.89%
Earnings Date
Last Earnings Date
Oct
22
Next Earnings Date
Feb
4
Estimated Next Earnings Date
Jan
21
Balance Sheet
VKTX
Sector
Total cash
$714.6M
$26.2M
Short term investments
$875.9M
$25.7M
Total assets
$908.3M
$76.7M
Long term debt
$318K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
